Related Stories
Progress
For Sopharma AD this effort is another contribution to an excellent corporate governance file.
Financial structure | |||||
---|---|---|---|---|---|
BGN '000 | 31.12.2024 | 31.12.2023 | 31.12.2022 | 31.12.2021 | 31.12.2020 |
Total debt capital | 480 852 | 351 551 | 283 295 | 330 622 | 425 329 |
Loans from banks | 371 305 | 263 072 | 195 872 | 269 766 | 321 020 |
Leasing and factoring obligations | 109 547 | 88 479 | 87 423 | 60 856 | 104 309 |
Cash and cash equivalents | 35 730 | 128 879 | 19 635 | 37 717 | 25 293 |
Net debt | 445 122 | 222 672 | 268 979 | 292 905 | 400 190 |
Equity attributable to equity holders of the parent | 818 105 | 738 332 | 704 658 | 646 975 | 553 269 |
Non-controlling interest | 24 998 | 15 294 | 11 976 | 11 893 | 13 326 |
Total equity | 843 103 | 753 626 | 716 634 | 658 868 | 566 595 |
Net debt/Total equity | 53% | 30% | 38% | 44% | 71% |
Net debt/EBITDA | 3,15 | 1,45 | 1,92 | 2,51 | 4,33 |